Israel Englander’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-71,300
| Closed | -$2.28M | – | 5820 |
|
|
2024
Q4 | $2.28M | Buy |
71,300
+53,700
| +305% | +$1.61M | ﹤0.01% | 3524 |
|
|
2024
Q3 | $508K | Sell |
17,600
-1,000
| -5% | -$37K | ﹤0.01% | 4825 |
|
|
2024
Q2 | $713K | Sell |
18,600
-31,400
| -63% | -$1.42M | ﹤0.01% | 4364 |
|
|
2024
Q1 | $2.94M | Sell |
50,000
-75,500
| -60% | -$4.81M | ﹤0.01% | 3391 |
|
|
2023
Q4 | $7.51M | Buy |
125,500
+84,500
| +206% | +$4.29M | ﹤0.01% | 2440 |
|
|
2023
Q3 | $1.56M | Sell |
41,000
-51,200
| -56% | -$2.25M | ﹤0.01% | 3802 |
|
|
2023
Q2 | $8.4M | Buy |
92,200
+62,200
| +207% | +$5.37M | ﹤0.01% | 2189 |
|
|
2023
Q1 | $1.98M | Buy |
+30,000
| New | +$1.73M | ﹤0.01% | 3460 |
|
|
2022
Q3 | – | Sell |
-170,000
| Closed | -$7.69M | – | 7037 |
|
|
2022
Q2 | $7.69M | Buy |
170,000
+150,000
| +750% | +$6.84M | ﹤0.01% | 2339 |
|
|
2022
Q1 | $1.02M | Sell |
20,000
-180,000
| -90% | -$7.95M | ﹤0.01% | 4498 |
|
|
2021
Q4 | $9.46M | Buy |
200,000
+150,000
| +300% | +$5.91M | ﹤0.01% | 2201 |
|
|
2021
Q3 | $1.65M | Buy |
50,000
+34,800
| +229% | +$1.96M | ﹤0.01% | 4138 |
|
|
2021
Q2 | $961K | Sell |
15,200
-84,800
| -85% | -$4.38M | ﹤0.01% | 4704 |
|
|
2021
Q1 | $4.29M | Buy |
+100,000
| New | +$4.73M | ﹤0.01% | 2749 |
|
|
2020
Q4 | – | Sell |
-100,000
| Closed | -$3.02K | – | 5171 |
|
|
2020
Q3 | $3.02K | Buy |
+100,000
| New | +$2.99M | ﹤0.01% | 2275 |
|
|
2020
Q1 | – | Sell |
-225,000
| Closed | -$6.89M | – | 3810 |
|
|
2019
Q4 | $6.89M | Sell |
225,000
-75,000
| -25% | -$2.08M | 0.01% | 1665 |
|
|
2019
Q3 | $7.23M | Buy |
+300,000
| New | +$8.26M | 0.01% | 1514 |
|
Other funds holding APLS
Israel Englander's APLS Position: Q2 2026 in Review
Israel Englander sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 2,256,802 shares — an estimated $90.8M sold.
Israel Englander first reported a position in APLS in Q2 2018 and held it in 30 quarters. The position peaked at $90.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Israel Englander reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Israel Englander sold 2,256,802 Apellis Pharmaceuticals shares in Q2 2026, an estimated $90.8M.
- Israel Englander first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 30 quarters.
- Israel Englander's Apellis Pharmaceuticals position peaked at $90.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.